SYDNEY, May 26, 2023 ~ FivepHusion, a clinical-stage biotechnology company, has announced a collaboration with Treehill Partners and Syneos Health® to develop and bring a novel, enhanced chemotherapeutic product to market.

Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, will provide FivepHusion with integrated business development, operational, strategic and transactional expertise. Syneos Health will support FivepHusion's integrated clinical development and commercialization capabilities. This collaboration is designed to strategically and optimally progress the development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol™ in global markets.

More on S For Story

• Does America Really Owe Blacks for Slavery?
• Devan the Deer Meet the Forest Animals Kids Book
• ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
• New Speculative Science Fiction Novel - Rise of the Wanderers By Elliott Morreau
• Bitcoin Mining Capacity Reaches 350 Exahashes/second

Dr. Christian Toouli, CEO & Managing Director of FivepHusion said: "This is a very exciting time for FivepHusion. We are at a crucial stage in our growth strategy. By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol™ to global markets."

Christian Tucat, Chief Business Officer of Syneos Health added: "Leveraging our deep therapeutic and global expertise, Syneos Health is pleased to contribute to accelerating the clinical development and commercialization of this important new therapy."

Ali Pashazadeh, Partner & Co-founder of Treehill Partners commented: "This collaboration represents a new model of integrated services across disciplines designed to allow US and non-US emerging players to play a key role on the global stage."

The collaboration between these three industry leaders is intended to maximize progress on the development of Deflexifol™ and quickly bring innovative oncology medicines to patients in need.

---

Show All News | Report Violation